A clinical trial found that the cholesterol drug Tredaptive increased the rate of side effects such as bleeding and infections, while failing in its ostensible purpose of reducing stroke, heart attack, death or the need for surgery in patients with vascular disease.
According to a Bloomberg report, researchers presented the study of 25,673 patients at the American College of Cardiology meeting in San Francisco.
Tredaptive’s manufacturer, Merck, has suffered from other recent ...
continue reading...
A story in the Huffington Post says there’s been an alarming increase in diabetes in recent years. Officials with the U.S. Centers for Disease Control and Prevention project that as many as one in three Americans could have diabetes by 2050 if current trends continue.
A blog post on Forbes deals with Johnson & Johnson’s type 2 diabetes drug Canagliflozin, which is expected to receive FDA approval soon and which the report describes as having “blockbuster potential.”
Shares of pharmaceutical companies that make newer types of diabetes medication have fallen, following the U.S. Food and Drug Administration’s announcement that the agency is looking into potential health risks, according to a March 14 story in Bloomberg.
